We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies.
- Authors
Tyler, Matthew A; Mohamed, Abdallah S R; Smith, Joshua B; Aymard, Jeremy M; Fuller, Clifton D; Phan, Jack; Frank, Steven J; Ferrarotto, Renata; Kupferman, Michael E; Hanna, Ehab Y; Gunn, Gary B; Su, Shirley Y
- Abstract
<bold>Objective: </bold>To evaluate long-term global and site-specific health-related quality of life (HRQoL) in patients treated for sinonasal and nasopharyngeal malignancies.<bold>Study Design: </bold>Cross-sectional.<bold>Methods: </bold>One hundred fourteen patients with sinonasal and nasopharyngeal malignancies received surgery, radiation, systemic chemotherapy, or a combination thereof, with curative intent. Validated global ([EuroQol-5D] Visual Analogue Scale [EQ-5D VAS]) and disease-specific instruments (MD Anderson Symptom Inventory-Head and Neck [MDASI-HN], Anterior Skull Base Questionnaire [ASBQ]) were administered to patients who were both free of disease and had completed treatment at least 12 months previously. Associations between instruments, instrument domains, and specific clinical parameters were analyzed.<bold>Results: </bold>The median age was 55 years. The mean EQ-5D VAS, MDASI-22 composite score, and ASBQ score were 74 (standard deviation [SD] 21), 48 (SD 36), and 130 (SD 27), respectively. The most frequently reported high-severity items in MDASI-HN were dry mouth and difficulty tasting food. The most frequently reported high-severity items in ASBQ were difficulty with smell and nasal secretions. Advanced Tumor (T) classification was associated with worse overall ASBQ sum score (P = 0.02). ASBQ performance at home and MDASI-HN drowsy symptom items independently predicted worse global HRQoL as measured by the EQ-5D VAS (P < 0.001).<bold>Conclusion: </bold>Global HRQoL for survivors of sinonasal and nasopharyngeal malignancies after multimodality treatment approximates that of the U.S. population for the same age group. ASBQ and MDASI-HN correlate well with global HRQoL outcomes as measured by EQ-5D VAS. MDASI-HN and ASBQ elicited unique symptoms, highlighting the complex symptom burden experienced by these patients. Further studies should identify patients predisposed to reduced long-term QOL.<bold>Level Of Evidence: </bold>3 Laryngoscope, 130:86-93, 2020.
- Publication
Laryngoscope, 2019, Vol 129, Issue 2, pN.PAG
- ISSN
0023-852X
- Publication type
journal article
- DOI
10.1002/lary.27849